JB Chemicals Share Price Drops 2% as Company Reports Lower Q4 Profit and Decline in Revenue Margins

JB Chemicals & Pharmaceuticals reported a decline in its financial performance for the fourth quarter of FY26, with net profit, revenue and operating earnings all lower compared to the same period last year. 

The pharmaceutical company also witnessed pressure on operating margins during the quarter. Despite the softer quarterly numbers, the company’s domestic business and branded generics segment recorded growth over the full financial year. 

Shares of the company were trading lower during early market activity following the earnings announcement.

Q4 Profit Declines Year-on-Year

The company posted a consolidated net profit of ₹101.4 crore for the quarter ended March 2026, marking a decline of 30.4% from ₹145.7 crore reported in the corresponding quarter of the previous financial year.

Revenue from operations also declined during the quarter. The company reported revenue of ₹904.2 crore compared to ₹949.5 crore in the year-ago period, reflecting a drop of 4.8% on a year-on-year basis.

EBITDA and Margins Under Pressure

JB Chemicals reported EBITDA of ₹201.1 crore for the fourth quarter, compared to ₹226.4 crore in the same quarter last year. The decline in operating earnings resulted in pressure on margins during the reporting period.

The EBITDA margin stood at 22.2%, lower than 23.9% recorded a year earlier. The moderation in margins indicates a relatively weaker operational performance during the quarter.

Domestic Business Records Growth

While quarterly consolidated numbers remained subdued, the company’s India business registered moderate growth during the quarter. Revenue from the domestic segment rose 2% year-on-year to ₹526 crore.

For the full FY26 financial year, the India business recorded growth of 9%, reaching ₹2,461 crore. The company’s branded generics segment also expanded by 11% during the same period.

JB Chemicals Share Price Performance

Following the quarterly earnings announcement, shares of JB Chemicals & Pharmaceuticals were trading at ₹2,158.50 on 12 May 2026, down 2.29% from the previous closing level of ₹2,209.20.

Read More: Tata Chemicals Q4FY26 Results: Net Loss Widens Despite Steady Revenue Growth.

Conclusion

JB Chemicals & Pharmaceuticals reported lower profit and revenue in the fourth quarter, accompanied by a decline in operating margins. However, the company continued to witness growth in its India-focused business and branded generics portfolio over the course of FY26. Investors are likely to monitor future operational performance and margin trends in the coming quarters.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.